Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland and Norway.

Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is intended to restore the physiological…

Launch of TASECTAN® AF in Denmark

Noventure is glad to announce the launch of TASECTAN® AF in Denmark by its partner company Pharmaforce, thus setting a record time-to-market, after Noventure granted Pharmaforce exclusive…

Launch of TASECTAN® AF in Finland and Sweden

Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October).

Last April, Noventure granted…

UTIPRO® PLUS Launched in Denmark

We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Denmark. The product is commercialized under the brand UrinCUR / Utipro plus and it…

What we do
New publication for Utipro® Plus / Utipro® Plus AF

Let’s celebrate 2022 with a new paper on Utipro® Plus and Utipro® Plus AF!! We are pleased to announce the publication of a meta-analysis in which the benefit of the combination of a…